Tissue Acquisition Research Group

组织获取研究小组(TRG)，也被称为RA/SLE加速药物伙伴关系 联合组织获取研究网络(ACTARN)专注于提供协议， 基础设施、质量控制和样品管理服务，以实现最佳样品 高质量标本的采购、加工、临时储存和适当的运输 用于审问、实验数据生成和分析评估的AMP站点。汇集了近几个 来自美国各地的20名研究人员，他们在系统性自身免疫性疾病方面拥有不同的经验和专业知识 针对器官损伤的研究，我们提出了分布式领导模式，以确保多样化 调查人员、机构和疾病状态专家参与其中，与LC和 UH2/UH3选定的地点，以制定最佳协议和标准操作程序(SOP) 采购、加工、储存、运输和使用生物标本给核准的项目和 网站，从而最大限度地利用这些宝贵的资源。我们的具体目标是完成这些活动 包括： 1)创建多机构、跨学科、协作的AMP联盟组织获取 研究网络(ACTARN)，以获取和分发AMP研究的高质量样本。 2)制定和完善采购准则和标准作业程序； 系统性红斑狼疮、类风湿关节炎等自身免疫性疾病组织标本的加工与质量控制 AMP财团关心的疾病患者。 3)确保为AMP项目和技术提供高质量、合适的样品 通过标本跟踪和处理以及提供临时储存进行评估， 样品库存管理和质量控制措施。 4)监督、协调临床研究站点，并将生物样本分发到 AMP网络领导委员会确定的技术研究站点。

The Tissue Acquisition Research Group (TRG), also called the RA/SLE Accelerating Medicines Partnership Coalition Tissue Acquisition Research Network (ACTARN) is focused on providing the protocols, infrastructure, quality control and sample management services which will allow for optimal sample procurement, processing, interim storage and appropriate shipping of high-quality specimens to collaborative AMP sites for interrogation, experimental data generation and analytic evaluation. Bringing together nearly 20 investigators from across the US with diverse experience and expertise in systemic autoimmune disease research and target organ damage, we propose a distributed leadership model to ensure that diverse investigators, institutions, and disease-state experts are involved, in concert with the rest of the LC and the UH2/UH3 selected sites, to develop the best protocols and standard operating procedures (SOPs) for the procurement, processing, storage, shipping and utilization of biologic specimens to approved projects and sites, thereby maximizing use of these precious resources. Our specific aims to complete these activities include: 1) Create a multi-institution, cross-disciplinary, collaborative AMP Coalition Tissue Acquisition Research Network (ACTARN) to obtain and distribute high quality samples for AMP studies. 2) Develop and refine guidelines and standard operating procedures for the procurement, processing and quality control of tissue specimens from SLE, RA and other autoimmune disease patients of interest to the AMP consortium. 3) Ensure delivery of high quality, appropriate samples for AMP projects and technologic evaluations through specimen tracking and processing, as well as providing interim storage, sample inventory management and quality control measures. 4) Oversee, coordinate with Clinical Research Sites, and distribute biological samples to Technology Research Sites as determined by the AMP Network Leadership Committee.